RGNX
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
REGENXBIO Inc. (RGNX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | D+ (1.7) | C- (2.1) | C (2.4) | C+ (2.6) | C (2.4) |
| 2026-11-07 | B- (3.0) | B (3.5) | C- (2.0) | C- (2.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-31 | B- (3.0) | B (3.3) | C- (2.1) | D+ (1.8) | F (0.0) | C- (2.1) |
| 2026-10-24 | B- (3.0) | B (3.3) | C- (2.0) | D+ (1.7) | F (0.0) | C- (2.0) |
| 2026-10-17 | B- (3.0) | B (3.3) | C- (2.0) | D+ (1.8) | F (0.0) | C- (2.0) |